Status:
NOT_YET_RECRUITING
Improving Diagnostic Safety Through STeatosis Identification, Risk Stratification, and Referral in the ED
Lead Sponsor:
Northwestern University
Collaborating Sponsors:
Agency for Healthcare Research and Quality (AHRQ)
University of Texas, Southwestern Medical Center at Dallas
Conditions:
Non-Alcoholic Fatty Liver Disease
Steatosis of Liver
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Hepatic steatosis is a common radiographic "incidental finding" that is overlooked and underreported to patients. The investigators developed a clinical decision support system using machine learning ...
Detailed Description
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a public health crisis affecting one third of the US adult population. Steatotic liver disease is an obesity related disease with se...
Eligibility Criteria
Inclusion
- imaging finding of hepatic steatosis on ED imaging study
- discharged from the ED to home
- first Northwestern Medicine ED visit in the study period with a hepatic steatosis finding
Exclusion
- admitted to the hospital
- age \< 18
- pre-existing Liver Disease diagnosis (Liver Cancer, HCV, HBV, Cirrhosis, NAFLD/MASLD/NASH/MASH, Alcohol Liver Disease, PSC, PBC and autoimmune hepatitis)
Key Trial Info
Start Date :
December 1 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 1 2028
Estimated Enrollment :
4704 Patients enrolled
Trial Details
Trial ID
NCT06944353
Start Date
December 1 2025
End Date
July 1 2028
Last Update
December 10 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Northwestern Memorial Hospital
Chicago, Illinois, United States, 60611